期刊文献+

中国云南汉族群体VKORC1基因多态性研究(英文)

Genetic Polymorphisms of VKORC1 in Han Population of Yunnan China
原文传递
导出
摘要 目的:探讨云南汉族人群维生素K环氧化物还原酶亚单位1(VKORC1)基因多态性,并与国内外群体进行比较。方法:采集280云南汉族心瓣膜置换术病人外周血,获得基因组DNA,用PCR-RFLP方法分析VKORC1-1639G/A,1173C/T,3730A/G的基因多态性。结果:对于VKORC1-1639G/A,共检出222(79.3%)名AA纯合子,8(2.8%)名GG纯合子,50(17.9%)名AG杂合子;对于VKORC1 1173C/T,检出224(80.0%)名纯合子TT,56(20.0%)名杂合子CT,未检出CC基因型;对于VKORC1 3730 A/G,共检出30(10.7%)名AA基因型,205(73.2%)名GG基因型,45(16.1%)名AG基因型。与不同群体相比,各位点差别不一。结论:与其他群体相比,云南汉族人群VKORC1-1639G/A,1173C/T,3730A/G基因位点具有自己的遗传多态性,其基因多态性在临床药物应用(如华法林)治疗中具有非常重要的意义。 Objective: To investigate the polymorphisms of VKORC1 in Han population of Yunnan China and compare it with that of other populations home and abroad. Methods: Blood samples were collected from 280 Chinese Yunnan Han patients with cardiac valves replacement. VKORC1-1639G/A, 1173C/T, 3730A/G polymorphisms were analyzed by polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP). Results: For VKORC1-1639G/A, 222 subjects(79.3%) were homozygous of AA, 8(2.8%)were GG, and 50(17.9%) were heterozygous of AG. Two hundred and twenty-four subjects(80.0%) were carriers of TT, while 56(20.0%) were CT, CC genotype was not found in VKORC1 1173C/T. VKORC1 3730 A/G showed that 45(16.1%) were heterozygote of AG, 30(10.7%) and 205(73.2%) were homozygote of AA and GG. Both similarities and differences in VKORC1 polymorphisms were found between Yunnan Han and other populations. Conclusions: This study increased the evidence of intrapopulation genotypic variability and highlighted the significant genotypic heterogeneity when different populations are considered, it would be useful to understand clinical pharmacokinetics and drug dosage recommendations for Yunnan Han population.
出处 《现代生物医学进展》 CAS 2015年第8期1409-1414,共6页 Progress in Modern Biomedicine
基金 国家自然科学基金项目(30860339) 云南省自然科学基金项目(2009ZC155M)~~
关键词 维生素K环氧化物还原酶亚单位1(VKORC1 vitamin K EPOXIDE REDUCTASE complex 1) 云南汉族人群 基因型 VKORC1(vitamin K epoxide reductase complex 1) Yunnan Han population Genotype
  • 相关文献

参考文献21

  • 1Farjadian S, Naruse T, Kawata H, et al. Molecular analysis of HLA allele frequencies and haplotypes in Baloch of Iran compared with related populations of Pakistan[J]. Tissue Antigens, 2004, 64 (5): 581-587.
  • 2Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORCI cause warfarin resistance and multiple coagulation factor deficiencytype2[J]. Nature, 2004, 427(6974): 537-541.
  • 3Li T, Chang CY, Jin DY, et al. Identification of the gene for vitamin Kepoxide reductase[J]. Nature, 2004, 427(6974): 541-544.
  • 4Veenstra DL, Chen G, Rettie AE. Association of vitamin K epoxide reductase complex I (VKORCI) variants in a Hong Kong Chinese population[J]. Pharmacogenet Genomics, 2005,10(15):687-691.
  • 5Wadelius M, Chen L, Lindh J, et al. The largest prospective warfarin-treated cohorts supports genetic forecasting[IJ. Blood, 2009, 113(4): 784-792.
  • 6Yuen E, Gueorguieva I, Wise S, et al. Ethnic differences in the population pharmacokinetics and pharmacodynamics ofwarfarin],l], J Pharmacokinet Pharmacodyn, 2010,37(1):3-24.
  • 7Yang J, Huang C, Shen Z, et al. Contribution of 1173C > T polymorphism in the VKORCI gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation[J]. International Journal of Clinical Pharmacology and Therapeutics, 2011, 49 (1): 23-29.
  • 8DAndrea G, DAmbrosio RL, Di Perna P, et al. A polymorphism in the VKORCI gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin[J]. Blood, 2005, 105 (2): 645-649.
  • 9Li T, Lange LA, Li X, et al. Polymorphisms in the VKORCI gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulationl J]. J Med Genet, 2006, 43(9): 740-744.
  • 10Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORCI genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen[J]. Blood,2005,106(7):2329-2333.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部